Table 1.
Baseline characteristics of patients included in the study
| Characteristics | Total patients (n = 246) | Included patients (n = 180) | Included patients BMI ≤ 25 (n = 78) | Included patients BMI > 25 (n = 102) |
|---|---|---|---|---|
| Age (years) | 47.6 ± 13.1 | 47.0 ± 12.7 | 42.9 ± 11.7 | 50.1 ± 12.6*** |
| Male | 146 (59) | 107 (59) | 39 (50) | 68 (67)* |
| Disease duration (years) | 10 (5–16) | 8 (5–16) | 7 (3–13) | 9 (6–18)** |
| SpA subtype | ||||
| Ankylosing spondylitis | 179 (78) | 140 (78) | 64 (82) | 76 (74) |
| Non-radiographic SpA | 49 (22) | 40 (22) | 14 (18) | 26 (26) |
| HLA-B27 | 174 (74) | 131 (73) | 61 (78) | 70 (69) |
| Psoriasis/IBD/uveitis | 71 (29) | 58 (32) | 27 (35) | 31 (30) |
| Peripheral arthritis | 97 (40) | 86 (48) | 38 (49) | 48 (47) |
| BASDAI | 5.8 ± 2.0 | 5.8 ± 2.0 | 5.5 ± 2.1 | 6.0 ± 1.9 |
| ASDAS | 3.3 ± 0.9 | 3.3 ± 1.0 | 3.2 ± 1.0 | 3.4 ± 1.0 |
| ESR (mmHg) | 17 (7–33) | 17 (7–31) | 19 (6–34) | 16 (7–31) |
| CRP (mg/L) | 5 (2–15) | 6 (3–17) | 7 (2–20) | 5 (3–15) |
| Previous TNFi | 43 (18) | 35 (19) | 13 (17) | 22 (21) |
| TNFi type | ||||
| Infliximab | 107 (43) | 74 (41) | 25 (32) | 49 (48)* |
| Adalimumab | 139 (57) | 106 (59) | 53 (68) | 53 (52)* |
| csDMARD | ||||
| Any csDMARD | 102 (42) | 79 (44) | 31 (40) | 48 (47) |
| MTX | 34 (15) | 25 (14) | 12 (15) | 13 (13) |
| SSZ | 46 (21) | 36 (20) | 10 (13) | 26 (25)* |
| MTX and SSZ | 22 (9) | 18 (10) | 9 (11) | 9 (9) |
| Prednisone | 22 (9) | 20 (11) | 11 (14) | 9 (9) |
The table shows mean ± SD, median (IQR) or absolute number (percentage) for all patients included (n = 180). The results are also stratified by body mass index (BMI). p value < 0.05 was considered statistically significant. Significant statistical differences between the groups of included patients, stratified by BMI: *p < 0.05, **p < 0.01, ***p < 0.001. SpA spondyloarthritis, HLA-B27 human leucocyte antigen B27, ESR erythrocyte sedimentation rate, CRP C-reactive protein, IBD inflammatory bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Index, TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine